April 21, 2023 /Lifestyle/ –The origin of 4/20 is a bit of a mystery. There are a few different stories about how it started, but the most likely explanation is that it originated with a group of high school students in San Rafael, California, in the early 1970s.
The students, who called themselves the Waldos, would meet at 4:20 p.m. every day after school to smoke marijuana. They chose the time because extracurricular activities had usually ended by then, and they were out of school but their parents weren’t home, giving them a window of unsupervised freedom.
NEW YORK, April 14, 2023 /Health/– Here are some of the top health news stories from this week:
New COVID-19 variant BA.2 spreads rapidly in Europe and the US
US Supreme Court to hear case on abortion rights
WHO reports more than 1 million deaths from COVID-19
New study finds that obesity can increase risk of dementia
Researchers develop new drug that could treat Alzheimer’s disease
Medaica, a digital health company extending the capability of home diagnostics, today announced that the U.S. Food and Drug Administration (FDA)-cleared1 Medaica M1 Telehealth Stethoscope (M1) will be free of charge, starting with qualifying strategic partners supporting rural or underserved patients with chronic heart and/or lung conditions. Continue reading
Roche (SIX: RO, ROG; OTCQX: RHHBY) introduces its navify® Algorithm Suite, a single platform hosting a library of digital medical algorithms that generate patient-centric insights and can aid earlier diagnosis of cancer and other conditions per intended use, at the HIMSS Global Conference in Chicago, USA, from April 17- 21, 2023. Continue reading
Proposed combination enhances Pfizer’s position as a leading company in Oncology
Seagen’s medicines, late-stage development programs and pioneering expertise in Antibody-Drug Conjugates (ADCs) strongly complement Pfizer’s Oncology portfolio
Seagen expected to contribute more than $10 billion in risk-adjusted revenues in 2030
Pfizer and Seagen to hold analyst and investor call at 8 a.m. EDT today
NEW YORK & BOTHELL, Wash.–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) and Seagen Inc. (Nasdaq: SGEN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines, for $229 in cash per Seagen share for a total enterprise value of $43 billion. The Boards of Directors of both companies have unanimously approved the transaction. Continue reading
One in six Black men in the United States will be diagnosed with prostate cancer in his lifetime versus one in eight white men. Black men are more likely to be diagnosed at a younger age, with more aggressive disease, and are more than twice as likely to die of prostate cancer. New findings from Prostate Cancer Foundation (PCF)-funded investigators shed light on the genetic underpinnings of this racial disparity and point the way toward more effective screening strategies. Continue reading